Search PubMedSearch

PubMed · 4459743

Routine proctosigmoidoscopy: how often?

Abstract

The cost-yield performance of routine proctosigmoidoscopy can be improved by far fewer examinations limited to the higher-risk patients. Since patients with diminutive polyps are at greater risk but diminutive polyps are rarely malignant and the doubling rate of colon cancer is slow, proctosigmoidoscopic examination of these higher-risk patients every 2 years is safe and more productive. Over 35 percent of those with original negative proctosigmoidoscopy demonstrate a new polyp on a second examination within 6 years. This significant shift into the higher-risk population warrants repeat proctosigmoidoscopy at least every 6 years in those without polyps.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Drexler. 1974. Routine proctosigmoidoscopy: how often?. https://doi.org/10.1159/000224971

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Crohn's disease.

Crohn's disease is a relapsing systemic inflammatory disease, mainly affecting the gastrointestinal tract with extraintestinal manifestations and associated immune disorders. Genome wide association studies identified susceptibility loci that--triggered by environmental factors--result in a disturbed innate (ie, disturbed intestinal barrier, Paneth cell dysfunction, endoplasmic reticulum stress, defective unfolded protein response and autophagy, impaired recognition of microbes by pattern recognition receptors, such as nucleotide binding domain and Toll like receptors on dendritic cells and macrophages) and adaptive (ie, imbalance of effector and regulatory T cells and cytokines, migration and retention of leukocytes) immune response towards a diminished diversity of commensal microbiota. We discuss the epidemiology, immunobiology, amd natural history of Crohn's disease; describe new treatment goals and risk stratification of patients; and provide an evidence based rational approach to diagnosis (ie, work-up algorithm, new imaging methods [ie, enhanced endoscopy, ultrasound, MRI and CT] and biomarkers), management, evolving therapeutic targets (ie, integrins, chemokine receptors, cell-based and stem-cell-based therapies), prevention, and surveillance.

Colonic Diseases